Actively Recruiting
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
Led by Takeda · Updated on 2026-04-13
8
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a survey in Japan of Brentuximab Vedotin used to treat children or teenagers with Hodgkin lymphoma (HL). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Brentuximab Vedotin especially myelosupression, peripheral neuropathy, and lung disorder. During the study, pediatric participants with HL will take Brentuximab Vedotin injection and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine) according to their clinic's standard practice. The study doctors will check for side effects from Brentuximab Vedotin for 26 weeks.
CONDITIONS
Official Title
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treatment-naive participants
- CD30 positive participants
- Participants treated with Brentuximab Vedotin combined with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD)
- Participants younger than 18 years at the start of treatment
You will not qualify if you...
- Participants with contraindications to Brentuximab Vedotin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Takeda selected site
Tokyo, Tokyo, Japan
Actively Recruiting
Research Team
T
Takeda Contact
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here